Articles related to TREATMENTS & PROCEDURES

Bevacizumab therapy demonstrated marked improvement in both epistaxis severity and abdominal symptoms, despite unchanged radiographic appearance of hepatic AVMs, suggesting therapeutic benefit at the microvasculature level.

The study’s findings highlight the complex interplay between CAR T cell therapy and cytokine signaling in AML treatment, suggesting new avenues for improving outcomes in this challenging disease.

Convincing bone loss would be bone loss at more than 1 site or over more than 1 interval, or bone loss associated with elevated markers of bone turnover such as cross-linked C-telopeptide of type-1 collagen (CTx) greater than 300 pg/mL.

GERD in infants can significantly impact growth and parent-child bonding, necessitating careful consideration of both non-pharmacological and pharmacological interventions.

The ABYSS trial questions the safety of interrupting long-term beta-blocker treatment in patients with a history of uncomplicated myocardial infarction, finding that discontinuation was not noninferior to continuation.

The trial found no significant difference in hospitalization or death risk between patients using long-term oxygen therapy for 24 hours versus 15 hours per day, potentially offering more freedom for those with severe hypoxemia.